From the “Phylogica Strategic Update - 4 December 2017” ... “As...

From the “Phylogica Strategic Update - 4 December 2017” ... “As part of the strategic review, the Board has determined that the significant further cost and internal resources required to further optimise the drug-like properties of the FPP-iMyc candidates will not be funded internally. However, the company will continue the iMyc program under the NHMRC grant received for this purpose (conducted externally) which includes in vivo validation studies. The Company is actively looking to out license the program as part of its strategy to concentrate on the delivery platform rather than single asset drug development.”

Does this mean we are waiting for a phone call from the Soucek team? At the quarterly Q&A at that time the CEO said in reply to a question about omoMYC that “if something comes along we’ll look at it”. It seems to me that PYC is not actively chasing MYC or a MYC deal and, indeed, commercialisation is on a 3-4 year timeline (I believe this was the reason it was shelved). So, I’m not sure if this is one to get excited about. I could be wrong - that’s happened before.